Stryker SYK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $3.21B-29.7% | $4.56B+20.0% | $3.8B+0.8% | $3.77B+23.4% | $3.06B-21.3% | |
| Orthopaedics: | $2.81B+7.8% | $2.61B+15.7% | $2.25B+0.1% | $2.25B-19.9% | $2.81B+10.0% | |
| Segment operating income by Business | ||||||
| MedSurg and Neurotechnology: | $700M-54.3% | $1.53B+38.9% | $1.1B+3.1% | $1.07B+41.2% | $757M-41.2% | |
| Orthopaedics | $846M-0.7% | $852M+31.3% | $649M-4.3% | $678M-20.6% | $854M+7.6% | |
| Reclassification to: cost of sales by Business | ||||||
| MedSurg and Neurotechnology: | $1.29B-23.9% | $1.7B+19.0% | $1.43B+0.8% | $1.41B+20.3% | $1.18B-20.7% | |
| Orthopaedics | $823M+14.0% | $722M+16.5% | $620M+3.5% | $599M-22.7% | $775M+15.3% | |
| Additions and adjustments by Business | ||||||
| MedSurg and Neurotechnology | -$74M-109% | $818.75M0.0% | $818.75M0.0% | $818.75M0.0% | $818.75M+284% | |
| Orthopaedics | $0+100% | -$250K0.0% | -$250K0.0% | -$250K0.0% | -$250K-100% | |
| Selling, general and administrative expenses by Business | ||||||
| MedSurg and Neurotechnology: | $930M-10.4% | $1.04B+6.8% | $972M-1.2% | $984M+14.6% | $859M-2.9% | |
| Orthopaedics | $880M+10.0% | $800M+7.8% | $742M-0.1% | $743M-19.7% | $925M+9.6% | |
| Research, development and engineering expenses by Business | ||||||
| MedSurg and Neurotechnology: | $231M+0.4% | $230M-6.9% | $247M+0.4% | $246M+18.3% | $208M+9.5% | |
| Orthopaedics | $146M+16.8% | $125M-5.3% | $132M+3.9% | $127M-19.6% | $158M+17.9% | |
| Reallocation of goodwill from MedSurg and Neurotechnology segments by Business | ||||||
| MedSurg and Neurotechnology: | -$518M— | —— | —— | —— | —— | |
| Orthopaedics | $518M— | —— | —— | —— | —— | |
| D&A by Business | ||||||
| MedSurg and Neurotechnology: | $55M-16.7% | $66M+17.9% | $56M-3.4% | $58M+20.8% | $48M+26.3% | |
| Orthopaedics | $119M+8.2% | $110M-0.9% | $111M+6.7% | $104M-2.8% | $107M-0.9% | |
| Foreign exchange and other by Business | ||||||
| MedSurg and Neurotechnology | -$19M-204% | $18.25M0.0% | $18.25M0.0% | $18.25M0.0% | $18.25M-15.1% | |
| Orthopaedics | -$10M-145% | $22.25M0.0% | $22.25M0.0% | $22.25M0.0% | $22.25M+152% | |
| Capital Expenditures During Period by Business | ||||||
| MedSurg and Neurotechnology: | $58M-13.4% | $67M+15.5% | $58M-6.5% | $62M+87.9% | $33M-76.4% | |
| Orthopaedics | $41M-67.7% | $127M+86.8% | $68M+30.8% | $52M+6.1% | $49M-16.9% | |
| Goodwill by Business | ||||||
| MedSurg and Neurotechnology: | $11.95B-4.9% | $12.56B— | —— | —— | —— | |
| Orthopaedics | $7.24B+7.5% | $6.74B— | —— | —— | —— | |
| Net Sales by Product | ||||||
| Endoscopy | $868M-24.2% | $1.15B+27.8% | $896M-0.3% | $899M+3.7% | $867M-13.8% | |
| Hips | $460M-7.8% | $499M+9.2% | $457M-1.9% | $466M+5.2% | $443M-4.3% | |
| Instruments | $920M-0.5% | $925M+21.7% | $760M-1.0% | $768M-8.4% | $838M+6.1% | |
| Knees | $670M-10.5% | $749M+19.3% | $628M-1.9% | $640M+0.2% | $639M-7.0% | |
| Medical | $902M-29.8% | $1.28B+30.4% | $985M-0.5% | $990M+4.8% | $945M-17.3% | |
| Ortho Tech | $646M— | —— | —— | —— | $617M— | |
| Spine | $2M-75.0% | $8M+33.3% | $6M+20.0% | $5M-97.0% | $166M-10.8% | |
| Trauma and Extremities | $1.04B-4.7% | $1.09B+13.1% | $960M+0.3% | $957M+1.3% | $945M-5.1% | |
| Vascular | $517M-4.1% | $539M+2.7% | $525M+5.4% | $498M+22.7% | $406M+19.1% | |
| Net Sales by Geography | ||||||
| International | $1.54B-10.8% | $1.73B+16.4% | $1.49B+1.2% | $1.47B+2.9% | $1.43B-8.8% | |
| United States | $4.48B-17.7% | $5.44B+19.0% | $4.57B+0.4% | $4.55B+2.6% | $4.44B-8.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
